Vizsgálati helyszín

Leipzig

Leipzig, Saxony 04103, NémetországMég nincs intézményhez kötve

13futó vizsgálat
15lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 28 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Koszorúér-betegség4 vizsgálat
Sclerosis multiplex (SM)4 vizsgálat
Krónikus mieloid leukémia (CML)3 vizsgálat
Chronic spontaneous urticaria2 vizsgálat
Familiáris hiperkoleszterinémia2 vizsgálat
Időskori makuladegeneráció2 vizsgálat
Mielodiszplasztikus szindróma (MDS)2 vizsgálat
Stroke (szélütés)2 vizsgálat
Akut mieloid leukémia (AML)1 vizsgálat
Arthritis psoriatica1 vizsgálat
Áttétes emlőrák1 vizsgálat
Dermatomyositis and polymyositis (myositis)1 vizsgálat
és még 8
Fázis: 3. fázis10 vizsgálat
2. fázis4 vizsgálat
4. fázis2 vizsgálat
1. fázis1 vizsgálat
2/3. fázis1 vizsgálat
Állapot: Lezárult11 vizsgálat
Fut, nem toboroz8 vizsgálat
Toboroz5 vizsgálat
Leállították4 vizsgálat
Fő szponzor: Novartis Pharmaceuticals28 vizsgálat

Futó vizsgálatok

Toboroz
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
NCT07549516· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
NCT06551519· Novartis Pharmaceuticals· Forrás
Toboroz
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
NCT06517719· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany
NCT06991608· Novartis Pharmaceuticals· Forrás
Toboroz
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943· 2/3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
NCT05921994· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469· 1. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114· 3. fázis· Novartis Pharmaceuticals· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Krónikus mieloid leukémia (CML)1 toboroz
Prosztatarák1 toboroz
Sclerosis multiplex (SM)1 toboroz

Lezárt vizsgálatok

Lezárult
Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care
NCT06004453· Novartis Pharmaceuticals· Forrás
Toboroz
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
NCT05344469· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Lezárult
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
NCT05192941· 4. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
NCT05362903· Novartis Pharmaceuticals· Forrás
Lezárult
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
NCT05032157· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
NCT04679935· 4. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
NCT04632927· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
NCT04543331· Novartis Pharmaceuticals· Forrás
Leállították
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
NCT04150029· 2. fázis· Novartis Pharmaceuticals· Forrás
Leállították
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
NCT04251533· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
NCT04023552· 3. fázis· Novartis Pharmaceuticals· Forrás
Leállították
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
NCT03946670· 2. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
NCT06311383· Novartis Pharmaceuticals· Forrás
Leállították
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
NCT02967692· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
NCT01784068· 2. fázis· Novartis Pharmaceuticals· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 15.

Hibát jelzek